January Global Macro Monthly - Omicron to a Russian Rubicon
- 26 January 2022 (10 min read)
Key points
- Omicron cases appear to be peaking in countries exposed early, but it is spreading more broadly. Hospitalisations have been relatively light, but disruption is still likely.
- Russia-Ukraine border tensions are rising and having a spillover effect in energy and risk asset markets.
- Inflation rose in several developed jurisdictions in December but should be near peak. Omicron and geopolitics to keep rates elevated over the coming months. Visible disinflation expected after the Spring.
- Elevated inflation and tight labour markets are resulting in developed market central banks tightening policy sooner than previously expected. We expect the Federal Reserve to tighten policy in March, but the European Central Bank to hold off into 2023.
- The growth outlook is softer in the short-term reflecting Omicron disruption and an income squeeze. We also lower our US growth outlook on faster policy tightening.
Disclaimer
This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.
It has been established on the basis of data, projections, forecasts, anticipations and hypothesis which are subjective. Its analysis and conclusions are the expression of an opinion, based on available data at a specific date.
All information in this document is established on data made public by official providers of economic and market statistics. AXA Investment Managers disclaims any and all liability relating to a decision based on or for reliance on this document. All exhibits included in this document, unless stated otherwise, are as of the publication date of this document.
Furthermore, due to the subjective nature of these opinions and analysis, these data, projections, forecasts, anticipations, hypothesis, etc. are not necessary used or followed by AXA IM’s portfolio management teams or its affiliates, who may act based on their own opinions. Any reproduction of this information, in whole or in part is, unless otherwise authorised by AXA IM, prohibited.